June 17, 2022

Dear Administrator Brooks-LaSure,

We, the undersigned organizations, are members of the Stakeholder Forum on Antimicrobial Resistance (S-FAR), representing clinicians, scientists, public health, hospitals, patients, advocates, and the pharmaceutical and diagnostics industries. We urge CMS to finalize provisions in the FY 2023 Hospital Inpatient PPS Proposed Rule (CMS–1771–P) that would require hospitals and critical access hospitals to report antimicrobial use and resistance (AUR) data into the CDC’s National Healthcare Safety Network (NHSN) as a required measure to satisfy the Public Health and Clinical Data Exchange Objective. Enhanced data collection and reporting are key to combating the growing and urgent threat of antimicrobial resistance (AMR).

AMR is one of the greatest public health threats of our time. Drug-resistant infections sicken at least 2.8 million people and kill at least 35,000 people in the United States each year. In 2019, there were more deaths worldwide caused by antibiotic-resistant bacteria than those caused by either HIV or malaria. Additionally, antibiotic resistance accounts for direct health care costs of at least $20 billion and imposes broader economic and health systems costs as high as $1.2 trillion. If we do not act now, antibiotic resistant infections will be the leading cause of death by 2050 and could cost the world $100 trillion.

Effective antibiotics are essential to modern medicine as we know it. Clinicians rely heavily on antibiotics to treat serious and life-threatening infections that complicate procedures such as cancer chemotherapy, dialysis, Cesarean sections, care of wounds and burns, joint replacements, transplants, and other surgeries. And, as we have witnessed throughout the COVID-19 pandemic, antibiotics are also critical during public health emergencies—used to treat secondary bacterial infections, often in medically complex or ventilated patients, and to combat related spikes in healthcare-associated infections that occur more frequently when health care facilities are strained.
We agree with CMS’ assessment in the proposed rule that widespread reporting of antibiotic use and resistance data is essential to identifying and tracking emerging threats and to evaluate the impact of interventions to address antibiotic resistance. Without these data, clinicians and public health departments are left in the dark, leaving health systems and patient more vulnerable to deadly and costly outbreaks. Antimicrobial resistance and use data improve clinical decision-making and inform antimicrobial stewardship practices. CMS’s proposed mandatory requirement for NHSN reporting, as described in the FY 2023 IPPS Proposed Rule, will be a critical step in advancing U.S. efforts to combat antibiotic-resistant bacteria and to prepare for future superbug outbreaks and pandemics. The first U.S. National Action Plan for Combating Antibiotic Resistant Bacteria, released in 2015, included a goal of 95% of hospitals reporting antimicrobial use data to NHSN by 2020. While improvements have been made, we remain far from this goal, with about 1600 hospitals reporting antibiotic use or resistance data (or both) to NHSN as of February 2020. This new requirement is crucial to advance progress in this area.

This new policy should drive increased investment in NHSN from Congress and CDC to provide financial support and technical assistance to help facilities report data to NHSN, with a focus on small, rural and critical access facilities. Lack of resources should not be used as an excuse to delay implementation.

Thank you for the opportunity to provide input and for your continued leadership on this issue. If you have any questions or would like to speak with S-FAR members, please contact Amanda Jezek, IDSA Senior Vice President of Public Policy and Government Relations, at ajezek@idsociety.org or Kyle Kinner, Director of Government Relations at The Pew Charitable Trusts, at kkinner@pewtrusts.org.

Sincerely,

Sincerely,

AdvaMedDx
American Academy of Allergy, Asthma & Immunology
American Public Health Association
American Society for Microbiology
American Society of Plastic Surgeons
AMR Action Fund
AMR Solutions
Antibiotic Resistance Action Center, George Washington University
Association of Public Health Laboratories
Association of State and Territorial Health Officials
Biotechnology Innovation Organization
Center for Biological Diversity
Center for Science in the Public Interest
CISAP
Consumer Reports
Cystic Fibrosis Foundation
Duke-Margolis Center for Health Policy
Emory Antibiotic Resistance Center
Food Animal Concerns Trust
Global Coalition on Aging
GSK
Health Care Without Harm
HealthyWomen
Hesed Foundation, Hesed Medical Associates
HIV Medicine Association
Infectious Diseases Society of America
International Foundation for Arthritis
Johns Hopkins Center for a Livable Future
Merck
Making A Difference in Infectious Diseases
Microbion Corporation
National Association of Pediatric Nurse Practitioners
NTM Info & Research
ONCORD, Inc.
One Health Trust
Partnership to Fight Infectious Disease
Pediatric Infectious Diseases Society
Peggy Lillis Foundation
Sepsis Alliance
Small World Initiative
Social Innovation in Drug Resistance Program, Boston University
Society of Infectious Diseases Pharmacists
The Coalition for Improving Sepsis and Antibiotic Practices
The Gerontological Society of America
The Pew Charitable Trusts
The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts
Trust For America’s Health
University of Nebraska Medical Center
Venatorx Pharmaceuticals